Sector portfolio · Private equity · United States
EcoR1 Capital's Biotech portfolio
EcoR1 Capital has backed 16 Biotech startups in rounds we track, $3.7B between them, shown by the stage each has reached. The best-funded is Nuvation Bio.
Funding by segment
- Series C and later$1.8B7
- Series B$1.1B6
- Series A$790M3
Where they are based
- United States15$3.6B
United StatesFounded
5 without a founding year on record.
Total raised
- Under $1M0
- $1M to $10M0
- $10M to $50M2
- $50M to $250M8
- $250M to $1B6
- $1B and over0
Each dot is a startup: the year it was founded across, the total it has raised up (each line is ten times the one below). Pick a segment to pick it out.
11 of 16 startups shown; the rest have no founding year or amount on record.
- 1 to 2
- 3 to 7
- 8 to 24
- 25 to 99
- 100 and more
- United States15
Startups by country, 1 country in all.
Segment by segment
Series C and later
7 startups · $1.8B raised
ElevateBioElevateBio is a biotechnology company based in Waltham, Massachusetts, founded in 2017.United States$551M
Arcus BiosciencesArcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.United States$427M- AAtrecaAtreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.United States$313M
Dewpoint TherapeuticsDewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.United States$196M
MetacrineMetacrine is a clinical-stage bio pharmaceutical company focused on building an innovative pipeline of best-in-class drugs.United States$173M- CCodiakUnited States$77M
- OORICUnited States$50M
Series B
6 startups · $1.1B raised
Intellia TherapeuticsIntellia Therapeutics is a genome editing company that develops curative gene-editing treatments.United States$485M
Editas MedicineEditas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.United States$335M
AlloVirAlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.United States$120M
Atara BiotherapeuticsAtara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.United States$69M- PTPrevail TherapeuticsUnited States$50M
- AAvidityAvidity is a RNA therapeutics software solutions provider company.United States$32M
Series A
3 startups · $790M raised
Nuvation BioNuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.United States$675M- PPrevail-$75M
- AAccentUnited States$40M
How this map is made. Every startup here works in Biotech and has raised money in a round we track that names EcoR1 Capital as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.
More portfolio maps
All portfoliosRaising from investors like EcoR1 Capital?
Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.